8-K
filed April 26, 2024, 7:59 PM ET
ticker HALO
CIK 0001159036
other material
confidence high
sentiment neutral
materiality 0.15
Halozyme stockholders elect directors, approve executive compensation and charter amendment at 2024 annual meeting
HALOZYME THERAPEUTICS, INC.
- Barbara Duncan elected with 90.1M votes for, Mahesh Krishnan with 104.0M votes for, each to three-year term.
- Advisory vote on named executive officer compensation passed 102.9M for vs 2.2M against.
- Amendment to certificate of incorporation to exculpate officers approved 91.5M for vs 13.6M against; filed with Delaware on April 25.
- Ratification of Ernst & Young as auditor for FY2024 passed 114.9M for vs 0.6M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
HALOZYME THERAPEUTICS, INC. shareholders approved Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2024-04-25 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-04-25
Exact text from the filing
Proposal 1 : Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Barbara Duncan 90,120,424 15,016,536 161,704 10,383,116 Mahesh Krishnan, M.D. 103,968,663 1,164,017 165,984 10,383,116 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the compensation of the Company’s named executive officers at the 2024-04-25 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-04-25
Exact text from the filing
Proposal 2 : The advisory vote on the compensation of the Company’s named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 102,860,435 2,190,603 247,626 10,383,116 The foregoing proposal was approved.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
HALOZYME THERAPEUTICS, INC. shareholders approved Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers at the 2024-04-25 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2024-04-25
Exact text from the filing
Proposal 3: The vote on a proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 91,512,252 13,612,616 173,796 10,383,116 The foregoing proposal was approved.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
HALOZYME THERAPEUTICS, INC. shareholders approved Ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-04-25 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-04-25
Exact text from the filing
Proposal 4 : The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows: Votes For Votes Against Abstain Broker Non-Votes 114,912,469 647,868 121,443 — The foregoing proposal was approved.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.